PlexusDx vs Levity: GLP-1 Pricing, Products and Plans Compared (2026)

Last reviewed: September 8, 2026 Last updated: September 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

PlexusDx publishes this comparison and is one of the providers discussed. We use the same evidence rules for our own program and competing programs.

The short answer

Levity and PlexusDx serve different segments of the GLP-1 market: Levity dispenses FDA-approved branded medications—Ozempic, Mounjaro, and Wegovy—at $1,149–$1,549 for the first month (with promotional code WELCOME, captured September 4, 2026) and $1,199–$1,599 per month thereafter. PlexusDx offers compounded semaglutide and tirzepatide injections at $189 and $289 per month respectively (month-to-month rates), with no membership fees or promotional pricing. Over 12 months, Levity's Ozempic plan costs $14,338 total ($1,194.83 effective monthly); PlexusDx compounded semaglutide costs $2,268 ($189 monthly). Neither model guarantees uninterrupted supply or specific clinical outcomes, and the two product classes—branded FDA-approved drugs versus compounded preparations—differ in regulatory status, manufacturing oversight, and out-of-pocket cost. If you prioritize FDA-approved branded medication and your budget supports $1,200–$1,600 per month, Levity delivers that; if you want clinician-prescribed compounded GLP-1 therapy at a fraction of the cost, PlexusDx is built for that use case.

At-a-glance comparison: Levity vs PlexusDx

Levity pricing verified September 4, 2026, via intake checkout (no payment submitted); PlexusDx pricing current September 8, 2026.

Branded FDA-approved drugs versus compounded preparations

The central difference is product class. Levity dispenses Ozempic (semaglutide, FDA-approved for type 2 diabetes), Wegovy (semaglutide, FDA-approved for chronic weight management), and Mounjaro (tirzepatide, FDA-approved for type 2 diabetes). Each medication has completed Phase III trials, carries FDA approval for its labeled indication, and is manufactured under Current Good Manufacturing Practice regulations with batch-level quality control.

PlexusDx works with licensed 503A compounding pharmacies to prepare patient-specific semaglutide and tirzepatide formulations. Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. Compounded drugs differ from branded drugs in regulatory pathway, manufacturing oversight, and quality-control framework, and they are not interchangeable with branded products. The price difference—roughly $1,000 per month for semaglutide injection—reflects this regulatory and manufacturing distinction, not a difference in active pharmaceutical ingredient purity or therapeutic intent.

Like-for-like pricing: semaglutide injection

Levity offers two branded semaglutide injection products: Ozempic at $1,199 per month (refill rate) and Wegovy at $1,599 per month. The first month with promotional code WELCOME costs $1,149 and $1,549 respectively (captured September 4, 2026). Both prices are all-inclusive: medication, provider consult, ongoing care, and shipping. Supply is billed approximately every four weeks.

PlexusDx compounded semaglutide injection is $189 per month on a month-to-month plan, $169 per month with a three-month commitment, and $149 per month with a six-month commitment. All PlexusDx rates include the online provider visit, prescription, compounded medication, and shipping; no separate membership or consultation fees apply. Dose escalation or maintenance does not change the monthly price.

12-month cost comparison (our calculation):

• Levity Ozempic: $1,149 (first month) + 11 × $1,199 = $14,338 total, $1,194.83 effective monthly.
• Levity Wegovy: $1,549 (first month) + 11 × $1,599 = $19,138 total, $1,594.83 effective monthly.
• PlexusDx compounded semaglutide (MTM): 12 × $189 = $2,268 total, $189 monthly.
• PlexusDx compounded semaglutide (6-month commitment): 12 × $149 = $1,788 total, $149 monthly.

At month-to-month rates, Levity's Ozempic plan costs 6.3 times PlexusDx compounded semaglutide over one year; Wegovy costs 8.4 times PlexusDx. The gap narrows slightly when including Levity's first-month discount but remains substantial: $14,338 versus $2,268 for semaglutide injection therapy delivered continuously for 12 months.

Like-for-like pricing: tirzepatide injection

Levity dispenses Mounjaro (tirzepatide injection, FDA-approved for type 2 diabetes) at $1,299 per month (refill rate) after a first-month rate of $1,249 with code WELCOME. The price is all-inclusive and billed approximately every four weeks.

PlexusDx compounded tirzepatide injection is $289 per month (month-to-month), $269 per month (three-month commitment), or $249 per month (six-month commitment), also all-inclusive with same-price dosing.

12-month cost comparison (our calculation):

• Levity Mounjaro: $1,249 (first month) + 11 × $1,299 = $15,538 total, $1,294.83 effective monthly.
• PlexusDx compounded tirzepatide (MTM): 12 × $289 = $3,468 total, $289 monthly.
• PlexusDx compounded tirzepatide (6-month commitment): 12 × $249 = $2,988 total, $249 monthly.

One year of Levity Mounjaro costs $15,538 versus $3,468 for PlexusDx compounded tirzepatide month-to-month—a 4.5-fold difference. At PlexusDx's six-month rate, the annual cost is $2,988, roughly one-fifth of Levity's branded option.

Additional product options

Levity's verified catalog includes compounded liraglutide, though route and pricing were not captured in the September 4, 2026 research session. Levity does not advertise compounded semaglutide or tirzepatide on its primary marketing pages.

PlexusDx offers compounded semaglutide and tirzepatide in both injection and oral capsule forms, plus a microdose GLP-1 injection protocol at $129 per month (month-to-month). Oral semaglutide is $289/$269/$249 (MTM/3-mo/6-mo); oral tirzepatide is $349/$299/$279. The microdose protocol uses a lower starting dose of semaglutide and is designed for individuals seeking gradual appetite modulation or maintenance after weight loss.

Membership, billing, and cancellation

Neither Levity nor PlexusDx charges a separate membership or subscription fee. Both models bundle the provider consultation, prescription, medication, and shipping into a single recurring charge.

Levity bills approximately every four weeks and permits cancellation at any time, according to its marketing pages (captured September 4, 2026). PlexusDx month-to-month plans can be paused or canceled without penalty; three-month and six-month commitments require fulfillment of the chosen term but do not auto-renew into longer commitments.

Practical differences: dose flexibility, supply continuity, insurance

Levity dispenses pre-filled branded pens manufactured by Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro). Dose titration follows the FDA-approved label schedule, and each pen delivers a fixed range of doses. If branded supply is interrupted—whether by manufacturing shortages, insurance prior-authorization delays, or other factors—Levity's ability to fulfill orders depends on wholesaler inventory.

PlexusDx compounded formulations are prepared by 503A pharmacies in patient-specific vials. Dose adjustments can be made at each refill based on clinical response and tolerability, within the prescribing clinician's judgment. Compounded GLP-1 supply is generally less constrained than branded drug inventory, though no provider can guarantee uninterrupted availability. Neither Levity's branded medications nor PlexusDx's compounded preparations are typically covered by commercial insurance when prescribed for weight management in patients without type 2 diabetes; both are out-of-pocket models.

Review and reputation snapshot

PlexusDx holds a 4.3-star rating on Trustpilot, with 79 percent of reviews at five stars and 83 percent at four stars or higher (captured September 9, 2026). Levity maintains a Trustpilot profile, but no aggregate rating or review volume was available at the time of research (September 4, 2026). No substantive negative themes were identified in Reddit discussions of Levity during the same capture window.

Choose Levity if…

You prioritize FDA-approved branded medication with the clinical trial data, manufacturing oversight, and regulatory standing that accompanies drugs like Ozempic, Wegovy, and Mounjaro. You have $1,200–$1,600 per month available for out-of-pocket weight management therapy and prefer a pre-filled pen delivery system. You value the label-specific approval for chronic weight management (Wegovy) or are managing concurrent type 2 diabetes with a GLP-1 (Ozempic, Mounjaro). You want a provider that exclusively dispenses branded products and are comfortable with approximately four-week billing cycles.

Choose PlexusDx if…

You want clinician-supervised semaglutide or tirzepatide therapy at $189–$289 per month (injections, month-to-month rates) or as low as $149–$249 with a six-month commitment. You understand that compounded medications are not FDA-approved and differ in regulatory pathway from branded drugs, and you accept that trade-off for a significantly lower monthly cost. You prefer dose flexibility managed by your prescribing provider rather than a fixed pen titration schedule. You want options beyond injection—oral semaglutide or tirzepatide capsules, or a microdose GLP-1 protocol for maintenance—under the same pricing and care model. You value transparent per-month rates with no promotional introductory pricing or four-week billing approximations.

Methodology and freshness

Levity pricing, product availability, inclusions, billing terms, and promotional offers were verified September 4, 2026, through completion of the online intake and advancement to checkout without payment submission. First-month and refill rates for Ozempic, Mounjaro, and Wegovy were captured from the checkout screen and cross-referenced with Levity's marketing pages. PlexusDx pricing was confirmed September 8, 2026, from live product pages and internal rate tables. The 12-month cost figures are our calculations, derived by summing first-month and refill rates over a continuous 12-month period. No insurance reimbursement, manufacturer coupon, or third-party discount program was modeled. Trustpilot ratings and review distributions were captured September 4, 2026. We will update this comparison if either provider materially changes its published rates, product lineup, or terms.

Frequently Asked Questions

How do compounded semaglutide formulations differ from Ozempic or Wegovy?

Ozempic and Wegovy are FDA-approved branded drugs manufactured by Novo Nordisk under CGMP regulations. Compounded semaglutide is prepared by a licensed compounding pharmacy for an individual patient and is not FDA-approved. The two differ in regulatory pathway, manufacturing oversight, and quality-control framework, and they are not interchangeable, though both contain semaglutide as the active ingredient.

Why is Levity's pricing so much higher than PlexusDx?

Levity dispenses FDA-approved branded medications—Ozempic, Mounjaro, Wegovy—which carry the costs of Phase III clinical trials, regulatory approval processes, brand-name manufacturing, and wholesaler markups. PlexusDx offers compounded preparations made by 503A pharmacies, which do not undergo FDA pre-market review and have lower production and distribution costs. The price gap reflects the difference in product class and regulatory pathway.

Can I use insurance to cover Levity or PlexusDx?

Neither Levity's branded GLP-1s nor PlexusDx's compounded formulations are typically reimbursed by commercial insurance when prescribed for weight management in the absence of type 2 diabetes. Both operate as direct-to-patient, out-of-pocket models. You should confirm coverage and prior-authorization requirements with your insurer before assuming any reimbursement.

Does PlexusDx offer the same dose escalation schedule as branded drugs?

PlexusDx providers follow evidence-based titration protocols informed by the published dosing strategies for semaglutide and tirzepatide. However, because compounded formulations permit custom dosing, your provider may adjust the schedule based on your tolerance, response, and clinical goals. Branded pens deliver fixed increments per the FDA label; compounded vials offer more granular flexibility.

What happens if Levity or PlexusDx cannot fulfill my refill?

Neither provider guarantees uninterrupted supply. Levity's fulfillment depends on branded drug inventory from Novo Nordisk and Eli Lilly; shortages at the manufacturer or wholesaler level may delay shipments. PlexusDx compounded medications are generally less affected by branded-drug shortages, but compounding pharmacy capacity or ingredient availability can still cause delays. Both providers advise contacting support if a refill is late, but no legal or contractual remedy for supply interruption is documented in either service agreement.

Sources

• PlexusDx product pages and pricing (accessed September 8, 2026)
• Levity marketing pages, intake workflow, and checkout pricing (accessed September 4, 2026)
• Trustpilot profiles for PlexusDx and Levity (accessed September 4, 2026)
• Reddit search results for Levity GLP-1 service discussions (accessed September 4, 2026)

Compounded medication disclosure: Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. PlexusDx works with licensed 503A compounding pharmacies.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.